

Maria Shipkova

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8995783/publications.pdf>

Version: 2024-02-01

102
papers

4,827
citations

87888

38
h-index

98798

67
g-index

102
all docs

102
docs citations

102
times ranked

3702
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring, 2019, 41, 261-307.	2.0	374
2	Acyl Glucuronide Drug Metabolites: Toxicological and Analytical Implications. Therapeutic Drug Monitoring, 2003, 25, 1-16.	2.0	250
3	The Pharmacokinetic-Pharmacodynamic Relationship for Total and Free Mycophenolic Acid in Pediatric Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2002, 13, 759-768.	6.1	225
4	Identification of glucoside and carboxylâ€linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. British Journal of Pharmacology, 1999, 126, 1075-1082.	5.4	189
5	Pharmacokinetic and Metabolic Investigations of Mycophenolic Acid in Pediatric Patients After Renal Transplantation: Implications for Therapeutic Drug Monitoring. Therapeutic Drug Monitoring, 2000, 22, 20-26.	2.0	171
6	Surface markers of lymphocyte activation and markers of cell proliferation. Clinica Chimica Acta, 2012, 413, 1338-1349.	1.1	153
7	Determination of the Acyl Glucuronide Metabolite of Mycophenolic Acid in Human Plasma by HPLC and Emit. Clinical Chemistry, 2000, 46, 365-372.	3.2	149
8	Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea. Transplantation, 2003, 75, 665-672.	1.0	142
9	Induction of cytokine release by the acyl glucuronide of mycophenolic acid: a link to side effects?. Clinical Biochemistry, 2000, 33, 107-113.	1.9	141
10	Identification of a Pharmacologically Active Metabolite of Mycophenolic Acid in Plasma of Transplant Recipients Treated with Mycophenolate Mofetil. Clinical Chemistry, 1999, 45, 419-422.	3.2	140
11	Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clinical Chemistry, 1998, 44, 1481-1488.	3.2	121
12	Comparison of the Emit Immunoassay with HPLC for Therapeutic Drug Monitoring of Mycophenolic Acid in Pediatric Renal-Transplant Recipients on Mycophenolate Mofetil Therapy. Clinical Chemistry, 2002, 48, 517-525.	3.2	112
13	Area Under the Plasma Concentrationâ€™Time Curve for Total, But Not for Free, Mycophenolic Acid Increases in the Stable Phase After Renal Transplantation: A Longitudinal Study in Pediatric Patients. Therapeutic Drug Monitoring, 1999, 21, 498.	2.0	105
14	6-Thioguanine Nucleotideâ€™Adapted Azathioprine Therapy Does Not Lead to Higher Remission Rates Than Standard Therapy in Chronic Active Crohn Disease: Results from a Randomized, Controlled, Open Trial. Clinical Chemistry, 2007, 53, 1306-1314.	3.2	104
15	Therapeutic Drug Monitoring of Everolimus. Therapeutic Drug Monitoring, 2016, 38, 143-169.	2.0	102
16	Differences in Nucleotide Hydrolysis Contribute to the Differences between Erythrocyte 6-Thioguanine Nucleotide Concentrations Determined by Two Widely Used Methods. Clinical Chemistry, 2003, 49, 260-268.	3.2	98
17	Measurement of Erythrocyte Inosine Triphosphate Pyrophosphohydrolase (ITPA) Activity by HPLC and Correlation of ITPA Genotype-Phenotype in a Caucasian Population. Clinical Chemistry, 2006, 52, 240-247.	3.2	97
18	Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice. Therapeutic Drug Monitoring, 2016, 38, 170-189.	2.0	95

#	ARTICLE	IF	CITATIONS
19	Pharmacokinetics and Protein Adduct Formation of the Pharmacologically Active Acyl Glucuronide Metabolite of Mycophenolic Acid in Pediatric Renal Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 390-399.	2.0	93
20	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 150-200.	2.0	89
21	Association of Inosine Triphosphatase &A and Thiopurine S-Methyltransferase Deficiency with Adverse Events and Study Drop-Outs under Azathioprine Therapy in a Prospective Crohn Disease Study. <i>Clinical Chemistry</i> , 2005, 51, 2282-2288.	3.2	88
22	Validation of a Rapid and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for Free and Total Mycophenolic Acid. <i>Clinical Chemistry</i> , 2004, 50, 152-159.	3.2	84
23	Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016, 38, S1-S20.	2.0	78
24	Mycophenolate mofetil in organ transplantation: focus on metabolism, safety and tolerability. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2005, 1, 505-526.	3.3	77
25	Effect of Cyclosporine Withdrawal on Mycophenolic Acid Pharmacokinetics in Kidney Transplant Recipients With Deteriorating Renal Function: Preliminary Report. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 717-721.	2.0	70
26	LC-MS/MS as a tool for TDM services: Where are we?. <i>Clinical Biochemistry</i> , 2016, 49, 1009-1023.	1.9	65
27	Bioavailability of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium Is Differentially Affected by Pantoprazole in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 1196-1201.	2.0	59
28	Analytic Aspects of Monitoring Therapy with Thiopurine Medications. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 220-226.	2.0	54
29	Biomarkers as a Tool for Management of Immunosuppression in Transplant Patients. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 560-572.	2.0	54
30	Circulating cytokines as markers of systemic inflammatory response in severe community-acquired pneumonia. <i>Clinical Biochemistry</i> , 2004, 37, 204-209.	1.9	50
31	Glucuronidation in therapeutic drug monitoring. <i>Clinica Chimica Acta</i> , 2005, 358, 2-23.	1.1	47
32	Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue. <i>Proteomics</i> , 2004, 4, 2728-2738.	2.2	46
33	Phenotypic and Genotypic Analysis of Thiopurine S-Methyltransferase Polymorphism in the Bulgarian Population. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 631-636.	2.0	44
34	Proteins identified as targets of the acyl glucuronide metabolite of mycophenolic acid in kidney tissue from mycophenolate mofetil treated rats. <i>Biochimie</i> , 2007, 89, 393-402.	2.6	44
35	Analysis of ITPA Phenotype-Genotype Correlation in the Bulgarian Population Revealed a Novel Gene Variant in Exon 6. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 6-10.	2.0	40
36	Pharmacokinetics and Pharmacodynamics of Intensified versus Standard Dosing of Mycophenolate Sodium in Renal Transplant Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 503-511.	4.5	40

#	ARTICLE	IF	CITATIONS
37	Association Between Adverse Effects Under Azathioprine Therapy and Inosine Triphosphate Pyrophosphatase Activity in Patients With Chronic Inflammatory Bowel Disease. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 321-328.	2.0	40
38	Lymphocyte surface molecules as immune activation biomarkers. <i>Clinical Biochemistry</i> , 2016, 49, 347-354.	1.9	39
39	A new acute inflammatory syndrome related to the introduction of mycophenolate mofetil in patients with Wegener's granulomatosis. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 923-926.	0.7	38
40	Pharmacokinetics and Bioavailability of Mycophenolic Acid After Intravenous Administration and Oral Administration of Mycophenolate Mofetil to Heart Transplant Recipients. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 315-321.	2.0	34
41	Multi-center analytical evaluation of a novel automated tacrolimus immunoassay. <i>Clinical Biochemistry</i> , 2014, 47, 1069-1077.	1.9	32
42	Improved Method for Therapeutic Drug Monitoring of 6-Thioguanine Nucleotides and 6-Methylmercaptopurine in Whole-Blood by LC/MSMS Using Isotope-Labeled Internal Standards. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 313-321.	2.0	31
43	Determination of Thiopurine Methyltransferase Phenotype in Isolated Human Erythrocytes Using a New Simple Nonradioactive HPLC Method. <i>Therapeutic Drug Monitoring</i> , 2003, 25, 637-644.	2.0	30
44	The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients. <i>Journal of Heart and Lung Transplantation</i> , 2011, 30, 565-571.	0.6	30
45	Pharmacokinetic and Pharmacodynamic Drug Monitoring of Direct-Acting Oral Anticoagulants: Where Do We Stand?. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 180-191.	2.0	30
46	Comparability and Imprecision of 8 Frequently Used Commercially Available Immunoassays for Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 433-441.	2.0	29
47	Cyclosporin A Absorption Profiles in Pediatric Renal Transplant Recipients Predict the Risk of Acute Rejection. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 415-424.	2.0	28
48	Investigation of the Crossreactivity of Mycophenolic Acid Glucuronide Metabolites and of Mycophenolate Mofetil in the Cedia MPA Assay. <i>Therapeutic Drug Monitoring</i> , 2010, 32, 79-85.	2.0	27
49	Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite. <i>Clinical Biochemistry</i> , 2000, 33, 203-208.	1.9	26
50	Safety and Efficacy of Intensified Versus Standard Dosing Regimens of Enteric-Coated Mycophenolate Sodium in De Novo Renal Transplant Patients. <i>Transplantation</i> , 2011, 91, 779-785.	1.0	26
51	SYNERGISTIC EFFECTS OF SIROLIMUS WITH CYCLOSPORINE AND TACROLIMUS: ANALYSIS OF IMMUNOSUPPRESSION ON LYMPHOCYTE PROLIFERATION AND ACTIVATION IN RAT WHOLE BLOOD. <i>Transplantation</i> , 2004, 77, 1154-1162.	1.0	25
52	Multicenter Analytical Evaluation of the Automated Electrochemiluminescence Immunoassay for Cyclosporine. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 640-650.	2.0	23
53	Liquid chromatography tandem mass spectrometry for therapeutic drug monitoring of immunosuppressive drugs: Achievements, lessons and open issues. <i>TrAC - Trends in Analytical Chemistry</i> , 2016, 84, 23-33.	11.4	22
54	Quantification of Mycophenolic Acid in Plasma Samples Collected during and Immediately after Intravenous Administration of Mycophenolate Mofetil. <i>Clinical Chemistry</i> , 2001, 47, 1485-1488.	3.2	21

#	ARTICLE	IF	CITATIONS
55	Irinotecan in Cancer Patients with End-Stage Renal Failure. <i>Annals of Pharmacotherapy</i> , 2009, 43, 363-369.	1.9	20
56	Stability of Mycophenolic Acid and Mycophenolic Acid Glucuronide in Human Plasma. <i>Clinical Chemistry</i> , 1999, 45, 127-129.	3.2	19
57	Optimizing everolimus exposure when combined with calcineurin inhibitors in solid organ transplantation. <i>Transplantation Reviews</i> , 2017, 31, 151-157.	2.9	19
58	Improving Therapeutic Decisions: Pharmacodynamic Monitoring as an Integral Part of Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 111-114.	2.0	19
59	Determination of Thiopurine Methyltransferase Activity in Isolated Human Erythrocytes Does Not Reflect Putative in Vivo Enzyme Inhibition by Sulfasalazine. <i>Clinical Chemistry</i> , 2004, 50, 438-441.	3.2	18
60	cDNA Microarray Analysis Reveals New Candidate Genes Possibly Linked to Side Effects Under Mycophenolate Mofetil Therapy. <i>Transplantation</i> , 2004, 78, 1145-1152.	1.0	18
61	Mycophenolic Acid Interaction With Cyclosporine and Tacrolimus In Vitro and In Vivo. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 123-131.	2.0	18
62	Editorial: Immune monitoring in solid organ transplantation. <i>Clinical Biochemistry</i> , 2016, 49, 317-319.	1.9	18
63	Comparing the effect of isotopically labeled or structural analog internal standards on the performance of a LC-MS/MS method to determine ciclosporin A, everolimus, sirolimus and tacrolimus in whole blood. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 437-46.	2.3	18
64	Association Between Pharmacodynamic Biomarkers and Clinical Events in the Early Phase After Kidney Transplantation: A Single-Center Pilot Study. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 341-349.	2.0	17
65	The Impact of CYP3A4*22 on Tacrolimus Pharmacokinetics and Outcome in Clinical Practice at a Single Kidney Transplant Center. <i>Frontiers in Genetics</i> , 2019, 10, 871.	2.3	17
66	Pharmacokinetics and pharmacodynamics of mycophenolate sodium (ECâ€MPS) coâ€administered with cyclosporine in the earlyâ€phase postâ€kidney transplantation. <i>Clinical Transplantation</i> , 2012, 26, 57-66.	1.6	14
67	Increased Cyclosporine Concentrations in the Absence of Cyclosporine Administration. <i>Clinical Chemistry</i> , 2011, 57, 670-673.	3.2	13
68	Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients. <i>Transplantation</i> , 2017, 101, 2780-2788.	1.0	13
69	Differential Proteomic Analysis of Lymphocytes Treated With Mycophenolic Acid Reveals Caspase 3-Induced Cleavage of Rho GDP Dissociation Inhibitor 2. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 211-217.	2.0	12
70	Therapeutic Drug Monitoring of Everolimus: Comparability of Concentrations Determined by 2 Immunoassays and a Liquid Chromatography Tandem Mass Spectrometry Method. <i>Therapeutic Drug Monitoring</i> , 2017, 39, 102-108.	2.0	12
71	Evaluation of an Immunoassay for Mycophenolic Acid. <i>Therapeutic Drug Monitoring</i> , 2000, 22, 141.	2.0	11
72	The Monoethylglycinexylidide (MEGX) Test as a Marker of Hepatic Dysfunction in Septic Patients with Pneumonia. <i>Clinical Chemistry and Laboratory Medicine</i> , 2000, 38, 1125-8.	2.3	10

#	ARTICLE	IF	CITATIONS
73	MYCOPHENOLATE MOFETIL DECREASES ENDOTHELIAL PROSTAGLANDIN E 2 IN RESPONSE TO ALLOGENEIC T CELLS OR CYTOKINES1. <i>Transplantation</i> , 2000, 69, 1977-1981.	1.0	10
74	Determination of monoethylglycinexylidide by fluorescence polarization immunoassay in highly icteric serum samples: modified precipitation procedure and HPLC compared. <i>Clinical Chemistry</i> , 1998, 44, 1269-1274.	3.2	8
75	Analytical Validation and Cross-Validation of an NFAT-Regulated Gene Expression Assay for Pharmacodynamic Monitoring of Therapy With Calcineurin Inhibitors. <i>Therapeutic Drug Monitoring</i> , 2016, 38, 711-716.	2.0	8
76	Measurement of sirolimus concentrations in human blood using an automated electrochemiluminescence immunoassay (ECLIA): a multicenter evaluation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 764-775.	2.3	8
77	Atypical Pharmacokinetics and Metabolism of Mycophenolic Acid in a Young Kidney Transplant Recipient With Impaired Renal Function. <i>Therapeutic Drug Monitoring</i> , 2002, 24, 438-443.	2.0	7
78	CD26/dipeptidyl peptidase IV: A comparative study of healthy persons and kidney transplant recipients before and early after transplantation. <i>Clinical Biochemistry</i> , 2013, 46, 1383-1388.	1.9	7
79	Multicenter Evaluation of a New Electrochemiluminescence Immunoassay for Everolimus Concentrations in Whole Blood. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 59-68.	2.0	7
80	A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients: results at 1 year. <i>Clinical Nephrology</i> , 2013, 79, 421-431.	0.7	7
81	The acyl glucuronide metabolite of mycophenolic acid induces tubulin polymerization in vitro. <i>Clinical Biochemistry</i> , 2010, 43, 208-213.	1.9	6
82	Biomarkers in transplantation medicine: Guide to the next level in immunosuppressive therapy. <i>Clinica Chimica Acta</i> , 2012, 413, 1309.	1.1	6
83	Analytical Aspects of the Implementation of Biomarkers in Clinical Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016, 38, S80-S92.	2.0	6
84	Therapeutic Drug Monitoring of Antibiotic Drugs: The Role of the Clinical Laboratory. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 32-49.	2.0	6
85	Rapid and Sensitive Liquid Chromatography-Tandem Mass Spectrometry Method for Determination of Monoethylglycinexylidide. <i>Clinical Chemistry</i> , 2001, 47, 1853-1856.	3.2	5
86	Performance of a phosphoflow assay to determine phosphorylation of S6 ribosomal protein as a pharmacodynamic read out for mTOR inhibition. <i>Clinical Biochemistry</i> , 2016, 49, 1181-1187.	1.9	5
87	Simultaneous determination of mycophenolate and its metabolite mycophenolate-7-o-glucuronide with an isocratic HPLC-UV-based method in human plasma and stability evaluation. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2016, 76, 612-619.	1.2	5
88	Monoethylglycinexylidide (MEGX) liver function test is not compromised by 3-hydroxy MEGX in humans. <i>Hepatology</i> , 1998, 28, 1439-1440.	7.3	4
89	Regulation of IL2 and NUCB1 in Mononuclear Cells Treated With Acyl Glucuronide of Mycophenolic Acid Reveals Effects Independent of Inosine Monophosphate Dehydrogenase Inhibition. <i>Therapeutic Drug Monitoring</i> , 2009, 31, 31-41.	2.0	3
90	Validation of a high-performance liquid chromatography method for thiopurine S-methyltransferase activity in whole blood using 6-mercaptopurine as substrate. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 803-809.	2.3	3

#	ARTICLE	IF	CITATIONS
91	Preliminary report on the effect of xenoperfusion with human blood on cyclosporin A metabolism and cytochrome-P-4503A4-mRNA expression in a pig liver perfusion model. <i>Clinical Biochemistry</i> , 2001, 34, 53-57.	1.9	2
92	A Simple And Rapid High-performance Liquid Chromatographic Procedure for Determination Of Inosine 5'-monophosphate Dehydrogenase Activity in Isolated Human Mononuclear Blood Cells (Mbc). <i>Therapeutic Drug Monitoring</i> , 2005, 27, 253.	2.0	2
93	Clinical utility of therapeutic drug monitoring of mycophenolic acid in transplantation medicine: Where are we? / Der klinische Nutzen des Therapeutischen Drug Monitoring von MycophenolsÄure in der Transplantationsmedizin: Wo stehen wir?. <i>Laboratoriums Medizin</i> , 2009, 33, 88-98.	0.6	1
94	Biomarkers. , 2012, , 349-372.		1
95	Analytical evaluation of a real-time PCR-based DNA demethylation assay to assess the frequency of naturally occurring regulatory T cells in peripheral blood. <i>Clinical Biochemistry</i> , 2016, 49, 1173-1180.	1.9	1
96	T-Cell Surface Antigens and sCD30 as Biomarkers of the Risk of Rejection in Solid Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , 2016, 38, S29-S35.	2.0	1
97	Biomarker monitoring in immunosuppressant therapy. , 2016, , 125-152.		1
98	Therapie mit Thiopurin-Medikamenten - TDM und Pharmakogenomik der TPMT. Therapy with Thiopurine Drugs - TDM and Pharmacogenomics of TPMT. <i>Laboratoriums Medizin</i> , 2003, 27, 211-221.	0.6	0
99	Therapie mit Thiopurin-Medikamenten TDM " und Pharmakogenomik der TPMT/Therapy with Thiopurine Drugs " TDM and Pharmacogenomics of TPMT. <i>Laboratoriums Medizin</i> , 2003, 27, 211-221.	0.6	0
100	Analytic Aspects of Monitoring Therapy with Thiopurine Medications. <i>ChemInform</i> , 2005, 36, no.	0.0	0
101	Biomarker im Blut zur Individualisierung der immunsuppressiven Therapie nach der Transplantation solider Organe. <i>Laboratoriums Medizin</i> , 2014, 38, 333-343.	0.6	0
102	Biomarkers in blood for individualization of the pharmacotherapy with immunosuppressive drugs after transplantation of solid organs. <i>Laboratoriums Medizin</i> , 2015, 38, .	0.6	0